Teva Pharmaceutical Industries Ltd. ADR

NYS: TEVA

GO
/marketstate/country/us

After Hours

 --Real time quotes

Aug 11, 2022, 5:14 p.m.

/zigman2/quotes/205657894/composite

$

11.10

Change

+0.0100 +0.09%

Volume

Volume 33,916

Real time quotes

/zigman2/quotes/205657894/composite

Today's close

$ 11.20

$ 11.09

Change

-0.11 -0.98%

Day low

Day high

$11.06

$11.34

Open

52 week low

52 week high

$6.78

$11.34

Open

Company Description

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates...

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Valuation

P/E Current

30.27

P/E Ratio (without extraordinary items)

22.05

Price to Sales Ratio

0.58

Price to Book Ratio

0.93

Price to Cash Flow Ratio

3.78

Enterprise Value to EBITDA

7.57

Enterprise Value to Sales

2.16

Total Debt to Enterprise Value

0.74

Efficiency

Revenue/Employee

1,363,661.00

Income Per Employee

35,884.00

Receivables Turnover

3.55

Total Asset Turnover

0.33

Liquidity

Current Ratio

1.14

Quick Ratio

0.79

Cash Ratio

0.20

Profitability

Gross Margin

47.10

Operating Margin

19.36

Pretax Margin

4.15

Net Margin

2.63

Return on Assets

0.87

Return on Equity

4.20

Return on Total Capital

8.67

Return on Invested Capital

1.30

Capital Structure

Total Debt to Total Equity

229.31

Total Debt to Total Capital

69.63

Total Debt to Total Assets

49.44

Long-Term Debt to Equity

214.37

Long-Term Debt to Total Capital

65.10

Officers and Executives

Name Age Officer Since Title
Mr. Kåre Schultz 59 2017 President, Chief Executive Officer & Director
Dr. Eric Drapé 59 2013 Executive Vice President-Global Operations
Mr. Eli Kalif 48 2019 Chief Financial Officer & Executive Vice President
Ms. Lori A. Queisser 60 2015 Senior Vice President & Global Compliance Officer
Mr. John Nason - 2015 President-Biologics Operations

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
05/10/2018 Bridger Management LLC
Director
250,000   Acquisition at $19.32 per share. 4,830,000
05/09/2018 Bridger Management LLC
Director
500,000   Acquisition at $19.21 per share. 9,605,000
/news/latest/company/us/teva

MarketWatch News on TEVA

  1. Teva Pharmaceutical upgraded to buy from neutral at BofA Securities

    9:44 a.m. Aug. 5, 2022

    - Tomi Kilgore

  2. $4.4 Billion Opioid Settlement Gives Teva Stock a Boost

    3:32 a.m. July 28, 2022

    - Barron's Online

  3. Teva Stock Soars After Reaching $4.25 Billion Opioid Settlement

    6:14 a.m. July 27, 2022

    - Barron's Online

  4. Teva to pay $75 mln over 15 years to settle opioid claims from W. Va., plus pay $8 mln in legal fees

    9:46 a.m. May 25, 2022

    - Steve Gelsi

  5. Teva settlement with W. Va. also includes $27 mln worth of generic Narcan over 10 years

    9:46 a.m. May 25, 2022

    - Steve Gelsi

  6. W. Va. says Teva opioid agreement consistent with previously announced settlements

    9:46 a.m. May 25, 2022

    - Steve Gelsi

  7. Teva Pharmaceutical upgraded to neutral from underperform at BofA Securities

    9:36 a.m. May 17, 2022

    - Tomi Kilgore

  8. Pfizer to Buy Biohaven Pharmaceuticals for $11.6 Billion

    10:06 a.m. May 10, 2022

    - Barron's Online

  9. Teva CEO Sees a Final Opioid Settlement Coming This Year

    4:58 p.m. May 3, 2022

    - Barron's Online

  10. Teva now sees full-year revenue of $15.4 bln to $16.0 bln vs. prior guidance of $15.6 bln to $16.2 bln

    7:19 a.m. May 3, 2022

    - Ciara Linnane

  11. Teva now sees full-year EPS of $2.40 to $2.60, unchanged vs. prior guidance

    7:20 a.m. May 3, 2022

    - Ciara Linnane

  12. Teva lowers full-year revenue guidance

    7:19 a.m. May 3, 2022

    - Ciara Linnane

  13. Teva Q1 adj. EPS 55 cents; FactSet consensus 53 cents

    7:17 a.m. May 3, 2022

    - Ciara Linnane

  14. Teva Q1 revenue $3.661 bln, down 8%; FactSet consensus $3.598 bln

    7:18 a.m. May 3, 2022

    - Ciara Linnane

  15. Loading more headlines...
/news/nonmarketwatch/company/us/teva

Other News on TEVA

  1. Walgreens Helped Fuel San Francisco Opioid Epidemic, Judge Rules

    4:57 p.m. Aug. 10, 2022

    - Jennifer Calfas

  2. Walgreens Helped Fuel San Francisco Opioid Epidemic, Judge Rules

    4:57 p.m. Aug. 10, 2022

    - Jennifer Calfas

  3. Drugmaker Endo Says Bankruptcy Likely Imminent

    8:19 p.m. Aug. 9, 2022

    - Alexander Gladstone

  4. Miller Opportunity Trust 2Q 2022 Quarterly Investment Review

    10:21 a.m. Aug. 6, 2022

    - Seeking Alpha

  5. Why Teva Stock Trounced the Market on Friday

    5:04 p.m. Aug. 5, 2022

    - Motley Fool

  6. Is This Rare Berkshire Hathaway Miscue Finally a Buy?

    8:25 a.m. Aug. 3, 2022

    - Motley Fool

  7. Viatris: A Spinoff To Own

    10:40 p.m. Aug. 1, 2022

    - Seeking Alpha

  8. Teva Q2 Earnings: 5 Reasons Why Shares Rose By 30%

    1:10 p.m. July 28, 2022

    - Seeking Alpha

  9. Teva Tries to Put an End to the Opioid Wars

    7:03 a.m. July 28, 2022

    - David Wainer

  10. 10-Q: TEVA PHARMACEUTICAL INDUSTRIES LTD

    4:09 p.m. July 27, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  11. Teva adds a record 22% as 2Q update addresses opioid uncertainty

    12:36 p.m. July 27, 2022

    - Seeking Alpha

  12. Loading more headlines...

At a Glance

Teva Pharmaceutical Industries Ltd.

124 Dvora HaNevi'a Street

Tel Aviv, TA 6944020

Phone

972 39148213

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

Revenue

$51.19B

Net Income

$1.35B

Employees

37,537

/news/pressrelease/company/us/teva

Press Releases on TEVA

  1. Thursday's ETF with Unusual Volume: HEFA

    12:42 p.m. Today

    - MarketNewsVideo.com

  2. How To Trade Invalid Iqfeed Symbol TEVA

    11:02 a.m. Aug. 2, 2022

    - Stock Traders Daily

  3. Teva Reports Second Quarter 2022 Financial Results

    4:55 p.m. July 26, 2022

    - BusinessWire - BZX

  4. Certara Appoints Rosemary Crane as New Independent Board Member

    8:00 a.m. July 25, 2022

    - GlobeNewswire

  5. Teva Pharmaceutical (TEVA) Trading Report

    7:56 p.m. July 23, 2022

    - Stock Traders Daily

  6. Trend Tracker for Teva Pharmaceutical TEVA

    10:52 a.m. July 10, 2022

    - Stock Traders Daily

  7. Teva Pharmaceutical (TEVA) Trading Report

    5:27 p.m. June 30, 2022

    - Stock Traders Daily

  8. Teva Pharmaceutical TEVA Proactive Strategies

    10:36 p.m. June 20, 2022

    - Stock Traders Daily

  9. Migraine Treatment Drugs Market Size, Share | Global Report [2028]

    12:58 a.m. June 16, 2022

    - AmericaNewsHour

  10. Learn to Evaluate Teva Pharmaceutical (TEVA) using the Charts

    11:12 p.m. June 9, 2022

    - Stock Traders Daily

  11. Loading more headlines...
Link to MarketWatch's Slice.